Varenicline, a partial agonist of the α4β2 nicotinic acetylcholine receptor (α4β2-nAChR), is currently used to facilitate smoking cessation. Preclinical and clinical studies have suggested that this compound may also be effective in treating cognitive impairments in schizophrenia. However, it is unclear which nicotinic acetylcholine receptor subtypes may be involved because varenicline is not only a partial agonist for α4β2-nAChRs but also a full agonist for α7 nicotinic acetylcholine receptors (α7-nAChRs).
Aim:
We investigated the effects of varenicline, compared to the α4β2-nAChR partial agonist TC-2403 and the α7-nAChR full agonist PNU-282987, in a ketamine-based model of schizophrenia-like cognitive deficits on the attentional set-shifting task in rats. The second goal was to elucidate whether the procognitive efficacy of varenicline was due to the compound’s action on α4β2-nAChRs or α7-nAChRs.
Methods:
Ketamine was administered to rats for 10 consecutive days and the test was performed 14 days following the last injection. The tested compounds were administered 30 min prior to the attentional set-shifting task.
Results:
Varenicline, TC-2403 and PNU-282987 ameliorated ketamine-evoked set-shifting deficits. While the α4β2-nAChR antagonist dihydro-β-erythroidine and the α7-nAChR antagonist methyllycaconitine completely prevented the procognitive actions of TC-2403 and PNU-282987, respectively, varenicline’s effect was only partially blocked by any given antagonist. Moreover, the combined treatment with TC-2403 and PNU-282987 more effectively facilitated rats’ set-shifting ability than activation of either type of nicotinic acetylcholine receptor alone.
Conclusion:
The present findings demonstrated that varenicline’s actions on both α7-nAChRs and α4β2-nAChRs may be necessary to produce its full procognitive effect in the present experimental setting.
AlbuquerqueEXPereiraEFAlkondonM, et al. (2009) Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev89: 73–120.
2.
AlkondonMPereiraEFEisenbergHM, et al. (2000) Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal networks. J Neurosci20: 66–75.
3.
AllisonCShoaibM (2013) Nicotine improves performance in an attentional set shifting task in rats. Neuropharmacology64: 314–320.
4.
BeckerAPetersBSchroederH, et al. (2003) Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry27: 687–700.
5.
BirrellJMBrownVJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci20: 4320–4324.
6.
BristowLJEastonAELiYW, et al. (2016) The novel, nicotinic alpha7 receptor partial agonist, BMS-933043, improves cognition and sensory processing in preclinical models of schizophrenia. PLoS One11: e0159996.
7.
BrooksJMPershingMLThomsenMS, et al. (2012) Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: Reversal with an alpha7 nicotinic agonist. Neuropsychopharmacology37: 2476–2486.
8.
ChangeuxJP (2010) Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci11: 389–401.
9.
ClokeJMWintersBD (2015) alpha(4)beta(2) Nicotinic receptor stimulation of the GABAergic system within the orbitofrontal cortex ameliorates the severe crossmodal object recognition impairment in ketamine-treated rats: Implications for cognitive dysfunction in schizophrenia. Neuropharmacology90: 42–52.
10.
D’SouzaMSMarkouA (2012) Schizophrenia and tobacco smoking comorbidity: NAChR AChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology62: 1564–1573.
11.
EnomotoTFlorescoSB (2009) Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure. Prog Neuropsychopharmacol Biol Psychiatry33: 668–675.
12.
EsterlisIRanganathanMBoisF, et al. (2014) In vivo evidence for beta2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biol Psychiatry76: 495–502.
13.
FlorescoSBZhangYEnomotoT (2009) Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res204: 396–409.
14.
GoetghebeurPDDiasR (2014) The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia. Curr Pharm Des20: 5060–5068.
15.
GranonSFaurePChangeuxJP (2003) Executive and social behaviors under nicotinic receptor regulation. Proc Natl Acad Sci U S A100: 9596–9601.
16.
HashimotoKFujitaYShimizuE, et al. (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol519: 114–117.
17.
HongLEThakerGKMcMahonRP, et al. (2011). Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry68: 1195–1206.
18.
JonesKMMcDonaldIMBourinC, et al. (2014) Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats. Psychopharmacology (Berl)231: 673–683.
19.
KeilhoffGBeckerAGreckschG, et al. (2004) Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience126: 591–598.
20.
KingJHuangWChenW, et al. (2011) A comparison of brain and behavioral effects of varenicline and nicotine in rats. Behav Brain Res223: 42–47.
21.
Lange-AsschenfeldtCSchableSSuvoravaT, et al. (2016) Effects of varenicline on alpha4-containing nicotinic acetylcholine receptor expression and cognitive performance in mice. Neuropharmacology107: 100–110.
22.
LiuMETsaiSJJeangSY, et al. (2011) Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatry Res190: 79–84.
23.
LivingstonePDSrinivasanJKewJN, et al. (2009) alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci29: 539–550.
24.
McLeanSLGraysonBMarshS, et al. (2016) Nicotinic alpha7 and alpha4beta2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders. Behav Brain Res302: 73–80.
25.
McLeanSLIdrisNFGraysonB, et al. (2012) PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol26: 1265–1270.
26.
McNallyJMMcCarleyRWBrownRE (2013) Impaired GABAergic neurotransmission in schizophrenia underlies impairments in cortical gamma band oscillations. Curr Psychiatry Rep15: 346.
27.
MihalakKBCarrollFILuetjeCW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol70: 801–805.
28.
MiyauchiMNeugebauerNMOyamadaY, et al. (2016) Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behav Brain Res301: 204–212.
29.
National Institutes of Health Guide for the Care and Use of Laboratory Animals (2011) Guide for the Care and Use of Laboratory Animals, 8th edition. Washington (DC): National Academies Press (US).
30.
NeillJCBarnesSCookS, et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacol Ther128: 419–432.
31.
NikiforukA (2016) Serotonergic and cholinergic strategies as potential targets for the treatment of schizophrenia. Curr Pharm Des22: 2093–2116.
32.
NikiforukAGolembiowskaKPopikP (2010) Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol20: 37–48.
33.
NikiforukAKosTHolujM, et al. (2016) Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats. Neuropharmacology101: 389–400.
34.
NikiforukAKosTPotasiewiczA, et al. (2015) Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats. Eur Neuropsychopharmacol25: 1300–1313.
35.
NikiforukAPopikP (2012) Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology (Berl)220: 65–74.
36.
ObinuMCReibaudMMiquetJM, et al. (2002) Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Prog Neuropsychopharmacol Biol Psychiatry26: 913–918.
37.
PapkeRLWeckerLStitzelJA (2010) Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther333: 501–518.
38.
ParikhVKutluMGGouldTJ (2016) nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophr Res171: 1–15.
39.
PotasiewiczAHolujMKosT, et al. (2017) 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats. Neuropharmacology113: 188–197.
40.
PotasiewiczAKosTRavazziniF, et al. (2015) Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor. Br J Pharmacol172: 5123–5135.
41.
RadekRJKohlhaasKLRueterLE, et al. (2010) Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des16: 309–322.
42.
RobertsACRobbinsTWEverittBJ (1988) The effects of intradimensional and extradimensional shifts on visual discrimination learning in humans and non-human primates. Q J Exp Psychol B40: 321–341.
43.
RollemaHChambersLKCoeJW, et al. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology52: 985–994.
44.
RollemaHHajosMSeymourPA, et al. (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol78: 813–824.
45.
RushforthSLAllisonCWonnacottS, et al. (2010) Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: A novel use of the odour span task. Neurosci Lett471: 114–118.
46.
SchwartzJC (2011) The histamine H3 receptor: From discovery to clinical trials with pitolisant. Br J Pharmacol163: 713–721.
47.
ShimJCJungDUJungSS, et al. (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial. Neuropsychopharmacology37: 660–668.
48.
SmithRCAmiazRSiTM, et al. (2016). Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: A double-blind randomized trial. PLoS One11: e0143490.
49.
TerryAVJrPlagenhoefMCallahanPM (2016) Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology (Berl)233: 761–771.
50.
TideyJWRohsenowDJKaplanGB, et al. (2005) Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend80: 259–265.
51.
VelliganDBrennerRSicuroF, et al. (2012) Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res134: 59–64.
52.
WallaceJMarstonHMMcQuadeR, et al. (2014) Evidence that the attentional set shifting test in rats can be applied in repeated testing paradigms. J Psychopharmacol28: 691–696.
53.
WallaceTLCallahanPMTehimA, et al. (2011) RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther336: 242–253.
54.
Wildeboer-AndrudKMStevensKE (2011) The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice. Pharmacol Biochem Behav100: 17–24.
55.
WilliamsJMAnthenelliRMMorrisCD, et al. (2012) A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry73: 654–660.
56.
WoodCKohliSMalcolmE, et al. (2016) Subtype-selective nicotinic acetylcholine receptor agonists can improve cognitive flexibility in an attentional set shifting task. Neuropharmacology105: 106–113.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
